Abstract:Objective To investigate the immune response against Hepatitis B virus (HBV) in- duced by HBsAg recombinant adenovirus (Ad-S)-transduced dendritic cells (DCs) in HBV transgenic mice (HBV-Tg),and evaluate its potential in treating chronic HBV infection.Methods DCs were generated from bone marrow cells from the HBV Tg mice.and transfected with Ad-S (DC/Ad-S) or pulsed with HBsAg protein (DC/HBsAg).HBV-Tg mice were randomly assigned to receive either DC/Ad-S (n=10) or DC/HBsAg(n=10) or pcDNA3.1(+) S plasmid (n=6),and the same im munization schedule was repeated twice at 3 week intervals.Intracellular cytokines of splenic T cells, HBsAg-specific activity of splenic cytotoxic T lymphocyte (CTL),and HBsAg and anti-HBs and HBV DNA titers in sera were detected after immunization by flow eytometry,LDH release assay, ELISA and quantitative PCR,respectively.Hepatic injury was monitored at various time points after immunization by measuring serum alanine aminotransferase (ALT) activity.Tissue samples of the liver were stained with hematoxylin and eosin for histological analysis,and the expression of hepatitis B core Ag(HBcAg) and HBsAg was assessed by immunohistochemical analysis.Results DC/Ad-S stimulated splenic Tc more efficiently to secrete IFNγthan DC/HBsAg or pcDNA3. 1 (+)-S (P＜0.05 or P＜0.01),and induced stronger splenic HBsAg-specific CTL responses than that induced by DC/HBsAg (P＜0.05 or P＜0.01 at 10:1,20:1,40:1 of E:T ratio),which were stronger than that induced by DNA vaccination (all P＜0.01 at 10:1,20:1,40:1 of E:T ratio),at 1 or 2 weeks after immunization, respectively. The CTL response elicited by DC/Ad-S was transient, rising to strongest at 1 to 2 weeks after immunization and waning gradually thereafter,but reduced more slowly than that elicited by DC/HBsAg.The suppression of serum HBsAg and HBV DNA and the reduction of expression of HBcAg and HBsAg in liver from HBV-Tg mice induced by DC/Ad-S were the strongest in all groups of immunization,and the second was that induced by DC/HBsAg from 1 to 4 weeks after immunization.The serum anti-HBs titer and ALT activity were slightly elevated,and histological analysis of the liver displayed only a very slight focal inflammatory infiltration up to 4 weeks after immunization,and the inter-group differences were not significant.Conclusions HBsAg recombinant adenovirus-transduced DCs can induce Tcl and CTL response,reduce the titer of serum HBsAg and HBV DNA,and inhibite the expression of HBcAg and HBsAg in liver in HBV-Tg mice, stronger than that induced by HBsAg-pulsed DCs or plasmid DNA.

Immunization with HBsAg-Fc Fusion Protein Induces a Predominant Production of Th1 Cytokines and Reduces HBsAg Level in Transgenic Mice.

Immune Response Against Hepatitis B Virus Induced by HBsAg Recombinant Adenovirus-Transduced Dendritic Cells in BALB/c Mice

Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg.

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

TBK-1 Enhances Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccination of HBV Core Gene

Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Vaccination with A Fusion Dna Vaccine Encoding Hepatitis B Surface Antigen Fused to the Extracellular Domain of Ctla4 Enhances Hbv-Specific Immune Responses in Mice: Implication of Its Potential Use As A Therapeutic Vaccine

[Immune response to HBsAg can not be enhanced with B7-H1 protein vaccine]

Cytokine Levels Induced by Various Kinds of Hepatitis B Vaccines in Mice

Effect of Plasmid DNA on Immunogenicity of HBsAg–Anti-HBs Complex

[Suppression of the Antigen-Specific T Cell Immune Response by Co-Immunization with the HBV DNA Vaccine and Recombinant HBsAg].

Enhancing Cellular Immune Response to HBV M DNA Vaccine in Mice by Codelivery of Interleukin-18 Recombinant.

Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Transcriptional Analysis of Immune-Related Genes in Dendritic Cells from Hepatitis B Surface Antigen (Hbsag)-Positive Transgenic Mice and Regulation of Fc Gamma Receptor IIB by HBsAg-anti-HBs Complex.

Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant

[A Study of Immune Response to HBsAg Mediated by CD4+ Memory T Lymphocytes in Immunized HBV Transgenic Mice].

DNA-mediated Immunization to Hepatitis B Surface Antigen: Effects of a Plasmid Coexpressing Hepatitis B Surface Antigen and Interleukin-18

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

DNA Immunization with Fusion of CTLA-4 to Hepatitis B Virus (HBV) Core Protein Enhanced Th2 Type Responses and Cleared HBV with an Accelerated Kinetic

Enhancement of HBV Vaccine Immunogenicity with Combination of CsA and IL-2 Fusion Protein in Mice Skin Transplantation Model